10.01.2022 | ASO Author Reflections
ASO Author Reflections: Neoadjuvant Chemotherapy for High-Grade Appendiceal Neoplasms Before Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy, Closer to Evidence-Based Practice?
verfasst von:
Christopher W. Mangieri, MD, Edward A. Levine, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 4/2022
Einloggen, um Zugang zu erhalten
Excerpt
Routinely proceeding with neoadjuvant chemotherapy (NAT) before cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for high-grade appendiceal neoplasms is a common practice at many HIPEC centers. The proposed tenets of that practice are that NAT chemotherapy limits progression of disease, improves the chances of a complete cytoreduction, and serves as a surgical selection tool. Yet, published literature supporting a true efficacy of NAT chemotherapy is lacking.
1‐3 Conversely, the risk profile with frequently utilized chemotherapy regimens is real and well documented. …